The Effect of the Co-administration of BMS-790052 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate (Ortho Tri-Cyclen) in Healthy Female Subjects.

Trial Profile

The Effect of the Co-administration of BMS-790052 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate (Ortho Tri-Cyclen) in Healthy Female Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2015

At a glance

  • Drugs Daclatasvir (Primary) ; Ethinylestradiol/norgestimate
  • Indications Hepatitis C; Menopausal syndrome; Pregnancy
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 21 Sep 2015 Primary end points are changed as reported by ClinicalTrials.gov record.
    • 03 May 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 03 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top